Table S2 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer

Key Points

Vγ9Vδ2 T cells demonstrate an enhanced antitumor profile in triple-negative breast cancer, indicating potential for immune therapy.
Key findings show that the activation defects in T cells can be restored by targeting BTN3A, potentially improving treatment outcomes.
T cell exhaustion was linked to TCR signaling profiles, which may affect patient responses to therapies like anti–PD-(L)1.
Understanding T cell behavior in this context provides insights into improving therapies for aggressive breast cancer types.

Analysis reveals an antitumor profile in Vγ9Vδ2 T cells, suggesting anti–PD-(L)1 and BTN3A therapies may overcome activation defects.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Fattori et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share